)
Visual21 Nov 2025
Data center suppliers
Lisata Therapeutics (LSTA) investor relations material
Lisata Therapeutics Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary6 Nov, 2025
Executive summary
Achieved key development milestones for certepetide, with positive preliminary results from ASCEND, ILSTA, Sendafox, and CENDIFOX trials, supporting its potential in anti-cancer regimens and broad applicability in solid tumors.
Entered strategic alliances with GATC Health for AI-driven drug discovery and Catalent for global licensing of certepetide as a SMARTag ADC payload.
Advanced multiple clinical programs and expanded the development pipeline, with ongoing efforts to secure additional licensing and partnership opportunities.
Leadership team has extensive experience in biopharmaceutical development, aiming to address unmet medical needs in oncology.
Cash runway extended into Q1 2027 with no debt, reflecting disciplined expense management.
Financial highlights
Operating expenses for Q3 2025 were $4.4 million, down 17.3% year-over-year; R&D expenses decreased 22.9% to $2 million, and G&A expenses fell 12.1% to $2.5 million.
Net loss for Q3 2025 was $4.2 million, compared to $4.9 million in Q3 2024; net loss for the nine months ended September 30, 2025 was $13.6 million, down from $15.4 million in the prior year period.
Revenue for the nine months ended September 30, 2025 was $70,000, related to an upfront license fee.
Cash and cash equivalents stood at $19 million as of September 30, 2025, with a projected runway into Q1 2027.
Working capital was $17 million and stockholders' equity $17.4 million as of September 30, 2025.
Outlook and guidance
Anticipates a data- and transaction-rich period in upcoming quarters, with several key clinical and business milestones expected.
Final data from ASCEND and ILSTA trials expected in Q1 2026; additional Sendafox, BOLSTER, and CENDIFOX trial data anticipated in late 2025 and 2026.
Phase III trial preparation underway, contingent on capital acquisition and partnership formation.
Sufficient cash to fund operations for at least the next 12 months; additional financing likely needed by end of 2026 for long-term needs.
Ongoing efforts to secure non-dilutive funding, partnerships, and potential equity or debt issuances.
Elaborate on CENDIFOX's immune-hot finding
Catalent deal: future ADC development strategy
Which key clinical milestones does cash runway cover?
ASCEND Phase III funding strategy
CENDIFOX immuno-hot data: next steps
Addressing market's perceived undervaluation
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Lisata Therapeutics earnings date
Q4 202526 Feb, 2026
Next Lisata Therapeutics earnings date
Q4 202526 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Lisata Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cell-based therapies for the treatment of advanced-stage diseases. The company's research and development efforts are primarily centered on addressing unmet medical needs in oncology, cardiovascular, and other serious conditions. Lisata leverages its proprietary technologies to create therapeutic solutions that promote tissue repair and regeneration. The company serves the healthcare sector with a focus on advancing treatments in areas where current options are limited. The company is headquartered in Basking Ridge, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage